ALDEYRA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 20.01K shares, a 91.67% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 33.95K shares.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 274.16K shares, a 177.83% increase from fiscal 2024.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 98.68K shares, a 67.79% decline from fiscal 2023.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 306.33K shares, a 29.27% increase from fiscal 2022.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 236.96K shares, a 62.64% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 53.96K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 20.01K shares 10-Q · filed 2026-05-07 | 53.96K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 274.16K shares 10-K · filed 2026-02-27 |
| 2025-09-30 | 33.95K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | |
| 2025-03-31 | 240.21K shares 10-Q · filed 2025-05-14 | |
| 2024-12-31 | 98.68K shares 10-K · filed 2025-02-28 | |
| 2023-12-31 | 8.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | 306.33K shares 10-K · filed 2024-03-07 |
| 2023-09-30 | 288.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 236.96K shares 10-K · filed 2023-03-09 |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 634.21K shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 3.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | 634.21K shares derived: sum of 4 quarters · filed 2021-10-28 |
| 2021-06-30 | 87.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 836.01K shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 543.83K shares 10-Q · filed 2021-05-06 | 761.07K shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | 219.24K shares 10-K · filed 2021-03-11 |
| 2020-09-30 | 204.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 421.25K shares derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | 12.45K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | |
| 2020-03-31 | 2.00K shares 10-Q · filed 2020-05-07 | |
| 2019-12-31 | 202.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | 232.00K shares 10-K · filed 2020-03-12 |
| 2018-12-31 | 0.00 shares 10-K · filed 2019-03-08 | |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | 0.00 shares derived: sum of 4 quarters · filed 2018-08-09 |
| 2018-03-31 | 0.00 shares 10-Q · filed 2018-05-15 | 0.00 shares derived: sum of 4 quarters · filed 2018-05-15 |
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | 0.00 shares 10-K · filed 2018-03-29 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | 7.76K shares derived: sum of 4 quarters · filed 2017-11-09 |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | |
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-15 | |
| 2016-12-31 | 7.76K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | 103.80K shares 10-K · filed 2017-03-30 |
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-09 | |
| 2014-12-31 | 0.00 shares 10-K · filed 2015-03-23 | |
| 2013-12-31 | 0.00 shares 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |